Industry Pulse

Views & Analysis

5-years-of-biosimilars-in-the-US-Industry-Pulse

5 years of biosimilars in the US: what have we learned?

Biologics have created revolutionary treatment options that have transformed the care journey for hundreds of millions of patients worldwide.

Views & Analysis

Who could replace Sir Andrew Dillon at NICE?

With Sir Andrew Dillon announcing his retirement as chief executive of NICE, pharmaphorum discusses potential replacements for the man who is arguably the most influential figure in health

News

Click claims FDA okay for first-in-class schizophrenia DTx

Click Therapeutics has won the first-ever FDA approval for a treatment for the negative symptoms of schizophrenia, a DTx called Motivista.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks